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ABSTRACT
Background and the purpose of the study: The aim of the present study was to examine factors 
that may influence the protein binding of morphine 6-glucuronide (M6G), the most active 
metabolite of morphine. 
Methods:  An  enzyme-linked  immunoabsorbent  assay  technique  was  used  to  measure  the 
M6G concentration in serum of 18 healthy adults, 18 neonatal and 7 children with cancer. 
Total and free M6G concentrations were measured following equilibrium dialysis for 3 hrs 
and at physiological pH at 37°C. The influence of vincristine, methotrexate, 6-mercaptopurine, 
morphine, human albumin, alpha-1-acid glycoprotein, palmitic acid, oleic acid and pH on M6G 
protein binding was examined.  
Results:  M6G  was  66.87±0.73  percent  free  in  human  serum  at  physiological  pH  and 
temperature. The percentage free (unbound) was increased significantly by vincristine (4.33%) 
and methotrexate (9.68%), but 6- mercaptopurine and morphine had no significant effect on 
it. Free percentages of M6G was reduced by decreasing serum albumin concentration but was 
unaffected by the presence of alpa-1-acid glycoprotein (AAG) or changes in serum pH. Similar 
results were obtained in human serum albumin (HAS) solutions. Addition of palmitic acid and 
oleic acid reduced protein binding significantly by 6.3% and 7.4%, respectively. 
Major conclusion: Although M6G in this study was not highly bounded, but because of its high 
analgesic potency, any change in its free concentration due to concurrent medication or disease 
caused significant changes in its effects. This dearth of evidence has been implicated in the 
reluctance of professionals to be cautious in prescribing them to children, particularly in the 
neonatal period.  
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INTRODUCTION
Morphine is conjugated in the liver to morphine-6- 
glucuronide  (M6G,  10–15%)  and  morphine-3-
glucuronide  (M3G,  45–55%)  (1).  The  analgesic 
potency of M6G is significantly greater than that of 
morphine by itself (2) . It has been suggested that it is 
the major contributor to analgesia following morphine 
administration  (3).  Morphine  is  often  co-prescribed 
with  a  number  of  drugs  including  those  with  high 
protein binding and as a result in patients who receive 
morphine M6G protein binding could be influenced.
Previous studies have shown that M6G pharmacokinetics 
in children differ from adults (4) and considering 
the  potential  role  of  M6G  in  clinical  situations, 
it  is  surprising  that  little  is  known  about  its 
potential interactions with other drugs. Previously 
measurement of M6G protein binding was performed 
in a pooled plasma (5) and five plasma samples (6) 
without studying any determinants. Very little is known 
on the extent to which M6G is bound to protein in 
plasma and its binding determinants. This is potentially 
important when morphine is co-prescribed with anti-
cancer drugs. The aim of this study was to characterise 
the protein binding of M6G in children and neonates 
in health and cancer states, and to assess the impact of 
protein binding of some common antineoplastic agents 
and other determinants on M6G protein binding.
MATeRIAlS AND MeThODS
Materials
Morphine  6–glucuronide  (Sigma–Aldrich,  UK), 
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human serum albumin (HSA, Sigma–Aldrich, UK), 
human  alpha1-acid  glycoprotein  (AAG,  Sigma–
Aldrich,  UK),  palmitic  acid  (Sigma  Chemical 
Company), oleic acid (BDH Chemicals Ltd), Teflon 
equilibrium  dialysis  cells  (MSD  Dianorm),  and 
Spectrapor®  2  membrane  (molecular  weight  cut-
off,  12-14,000  daltons)  were  used  in  this  study. 
Sorensen’s phosphate buffer of 0.15 M containing 
0.59% sodium chloride with pH of 7.4 was prepared 
by the described method (7).
Methods
M6G concentration was measured by enzyme-linked 
immunosorbent  assay  (ELISA)  (8).  Serum  free 
percentage of M6G was determined by equilibrium 
dialysis  similar  to  determination  of  morphine 
protein binding (9). The examined concentration of 
M6G was within the therapeutic concentration range 
after morphine administration (4). One ml aliquots 
of spiked Sorensen’s buffer were added to Teflon 
equilibrium dialysis cells and dialyzed for 3 hrs at 
37°C against one ml aliquots of serum or protein 
solution. The two compartments were separated by a 
Spectrapor®  2 membrane. Any leakage or adhesion 
of the drug during the experiments was identified 
by  measurment  of  albumin  concentration  in  the 
protein compartment before and after dialysis and 
determination of M6G concentration in the chambers 
of the dialysis apparatus before and after dialysis 
and comparison of their total concentration with the 
originally  added  M6G.  Equilibrium  was  achieved 
within 120 min and remained stable for 180 min. 
Samples were run in duplicates. The percentages of 
unbound drug were calculated as percentages of the 
ratio of concentrations in the solutions of buffer and 
serum at the end of the dialysis.
Serum albumin concentrations were measured using 
Albumin  Reagent  (BCP)  purchased  from  Sigma 
Diagnostics®. AAG concentrations were measured 
using  a  “NOR  Partigen® α 1  -acid  glycoprotein” 
(Dade Behring) immunodiffusion plates.  
Determination of M6G protein binding in healthy 
adult subjects, neonates and children on treatment 
for cancer
Eighteen  healthy,  drug  free,  non-fasting  subjects 
were enrolled in the study. Blood was collected by 
direct venepuncture into polypropylene syringes into 
anticoagulant-free  glass  tubes.  The  samples  were 
centrifuged 30 min after collection at 3000 rpm for 
15 min. The serum albumin and AAG concentrations 
were  measured  immediately.  The  serum  samples 
were frozen at -20°C in glass tubes. Samples were 
thawed  within  1  week  for  estimation  of  protein 
binding. PH of the serum samples were measured 
immediately before and after dialysis. 
Neonatal blood sample collection was carried out 
at the Delivery Suite in Llandough Hospital. Blood 
was collected form the umbilical cord of newborn 
babies. Mothers who had received any opioid before 
or during delivery were excluded from the study. 
Samples were prepared by the same procedure which 
was explained before. 
Blood samples collected from children with cancer 
who received morphine as part of their treatment 
were  used  in  the  present  study.  After  collection 
of samples and separation of the serum, a serum 
sample  was  applied  to  the  normal  procedure  of 
protein  binding  measurement.  The  demographic 
information  for  children  with  cancer  has  been 
reported previously (4).
The research was conducted in accordance with the 
Declaration of Helsinki and the required permission 
for  collection  of  blood  from  healthy  adults,  the 
neonatal and children was received from Bro Taf 
Health Authority in Cardiff. 
Determination of effects of human serum albumin, 
AAG and nonesterified fatty acids (NEFAs) on M6G 
binding
In vitro studies were performed using HSA made up 
in a solution of Sorensen’s buffer (2.5, 5, 10, 20, 40, 
60, and 70 g/l) (9). The buffer was spiked with 50 
ng/ml of M6G.
Pure AAG (1.0 and 2.0 g/l), oleic acid (1.0 mmol) and 
palmitic acid (1.0 mmol) were added to a solution of 
40 g/l of HSA separately. Six cells of each solution 
were prepared and dialyzed against spiked Sorensen’s 
phosphate  buffers  with  50  ng/ml  of  M6G.  Control 
solutions were treated in an identical manner (9). 
Determination of effect of pH and M6G concentration 
on M6G binding
The effects of pH on serum protein binding of M6G 
were measured in the serum of a healthy volunteer. 
Serum samples were adjusted by HCl or NaOH to 
the desired pH values (7.0, 7.2, 7.4, 7.6, 7.8 and 8.0) 
and dialyzed against spiked Sorensen’s phosphate 
buffers  with  50  ng/ml  of  M6G  of  the  same  pH 
values. Other serum aliquots were left untreated and 
dialyzed against a range of phosphate buffer of pH 
between 7.0 and 8.0 (7.0, 7.2, 7.4, 7.6, 7.8 and 8.0).
M6G was added to the buffer to achieve pre-dialysis 
concentrations between 5 and 200 ng/ml. Equilibrium 
dialysis was performed against serum of a healthy 
volunteer.  M6G  concentrations  were  measured  in 
the serum chambers and their correlation with free 
M6G percentages was examined (9).
 
Determination of disposition of M6G by anti cancer 
drugs and morphine
The effects of three anti-cancer drugs; vincristine, 6- 
mercaptopurine (6MP) and methotrexate on protein 
binding of M6G, were studied and compared with 
a control sample of M6G (0 µg/ml of anti cancer 
drugs).  The  reported  maximum  concentration  of 
vincristine,  6MP  and  methotrexate  in  the  plasma 
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ml  (10),  653  ±  344  ng/ml  (11)  and  5  µM  (12), 
respectively. The protein binding of these agents 
are reported to be 71% (13), 20- 90% (14) and 
25-55% (15), respectively. In order to study the 
effects of therapeutics and toxic concentration of 
these drugs, three concentrations of each drug, one 
within normal plasma concentration, one close to 
the highest plasma concentration and one higher 
than maximum plasma concentration were chosen. 
Possible effect of morphine which is also present 
in the plasmaon M6G protein banding was also 
examined (9). None of the examined anti-cancer 
medications  were  administered  to  the  children 
with cancer at the time of blood collections.
Comparison of protein binding of M6G in serum and 
plasma sample 
Ten ml blood from one volunteer was collected into 
a lithium heparinised tube and another 10 ml added 
to a plain glass tube with no anti-coagulant. Both 
samples were centrifuged at 3000 rpm for 15 min 
before storage at -20° C. Equilibrium dialysis was 
performed in six cells for each sample (9).
Determination of the Effect of storage of blood and 
buffer samples on M6G binding
In order to investigate the effect of storage of serum 
samples at -20°C, blood from a non-fasting, drug 
free,  healthy  volunteer  was  collected.  The  serum 
was divided into 5 parts. Buffer was spiked with 50 
ng/ml of M6G which also divided into 5 parts. The 
first serum sample and buffer were applied to the 
equilibrium dialysis on the day of collection. The 
other samples were kept at -20° C until they were 
dialyzed after 7, 14, 21 and 28 days. 
Statistical analyses 
Statistical  calculations  were  carried  out  using  the 
computer software package “Prism”. ANOVA with 
Dunnett’s multiple comparison tests and unpaired 
t  test  analysis  were  used  to  detect  significant 
correlation between variables. Probability values of 
P < 0.05 were considered to be significant.
ReSUlTS
M6G  protein  binding  in  healthy  adult  subjects, 
neonates and children following treatment with anti-
cancer drugs
The percentage of free M6G in the serum of the 18 
adult subjects (10 male and 8 female) aged from 24 
to 53 years was 61.72 % ± 2.94. Their serum albumin 
concentration ranged from 33.0 to 51.0 g/l (43.8 ± 
4.4 g/l). The serum AAG was 0.8 ± 0.3 g/l and varied 
from 0.333 to 1.42. Albumin was the main binding 
protein for M6G. The binding ratio (bound/free) of 
M6G in these subjects was significantly related to 
albumin concentrations (R2 = 0.506, P = 0.0009). The 
relationship between free percentages of M6G and 
AAG concentration in the subjects failed to reach 
statistical  significance  (R2 =  0.198,  P  =  0.0644). 
There was no significant relationship between free 
percentages of M6G and serum pH before and after 
dialysis  (R2 =  0.001,  P  =  0.8932  and  R2 =  0.087, 
respectively, P = 0.2340). No significant correlation 
was  found  between  subjects’  age  and  M6G  free 
percentages  (R2 =  0.180,  P  =  0.0793).  Multiple 
regression analysis of effects of serum albumin and 
AAG concentration on M6G binding showed that 
there  was  a  significant  relationship  between  their 
concentrations and M6G free percentages in adult 
subjects (R2 = 0.543, P < 0.05) and effects of serum 
albumin concentration on M6G protein binding was 
significantly greater than effects of AAG on M6G 
protein binding.
In  neonatal  samples,  serum  albumin  and  AAG 
concentration  were  32.4  ±  3.0  g/l,  0.32  ±  0.1  g/l, 
respectively.  M6G  protein  free  percentages  in 
neonatal  samples  was  70.5%  ±  3.8  and  changed 
significantly  by  changes  in  serum  albumin 
concentration  (R2  =  0.407,  P  =  0.0044).  There 
was also a significant relationship between serum 
albumin concentration and the binding ratio of M6G 
(R2 =  0.420,  P  =  0.0036).  Unlike  albumin,  there 
was no significant relationship between M6G free 
percentages  and  serum AAG  concentration  (R2 = 
0.069, P = 0.294) or serum pH, either before or after 
dialysis (R2 = 0.200, P = 0.0626 and R2 = 0.250, P 
= 0.0544, respectively). Multiple regression analysis 
of effects of serum albumin and AAG concentration 
on  M6G  binding  percentages  showed  that  there 
was  a  weak  but  significant  relationship  between 
their concentrations and M6G free percentages in 
neonates subjects (R2 = 0.408, P = 0.02) and effects 
of  serum  albumin  concentration  on  M6G  protein 
binding were significantly greater than that of AAG 
concentration in serum on binding.
The free percentage of M6G in serum of children 
with cancer was 69.20 ± 4.26 and ranged from 62.33 
to 77.72%. It was significantly correlated to serum 
albumin concentration (R2 = 0.607, P = 0.039) but 
there  was  no  significant  relationship  with  serum 
AAG  concentration  (R2  =  0.092,  P  =  0.509)  or 
serum pH before and after dialysis (R2 = 0.009, P = 
0.8360 and R2 = 0.202, P = 0.2018, respectively). 
The M6G binding ratio was significantly related to 
serum albumin concentration in children (R2 = 0.644,                       
P = 0.03). Furthermore, M6G free percentages was 
not  significantly  related  to  its  concentration  after 
dialysis (R2 = 0.019, P = 0.769).
Multiple  regression  analysis  of  effects  of  serum 
albumin  and  AAG  concentration  on  M6G  free 
percentages  showed  that  there  was  a  significant 
relationship  between  these  parameters  in  children 
patients (R2 = 0.408, P = 0.02) and the effect of serum 
albumin concentration on M6G protein binding was 
significantly greater than AAG serum concentration 
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related  to  M6G  concentration  over  this  range  of 
concentrations (Figure 3).
Disposition  of  M6G  by  anti-cancer  drugs  and 
morphine
Increase in the concentration of vincristine caused 
an increase in the free M6G from 67.0% ± 0.9 to 
71.33% ± 1.6 (R2 = 0.978, P = 0.0113). Increasing the 
methotrexate concentration up to 1.5 µg/ml raised 
free percentage of M6G to 76.7% ± 3.2 (R2 = 0.952, 
P = 0.0243). Further increase in the concentration of 
these drugs, might result a larger raise in free M6G 
percentages. For morphine and 6-MP, no significant 
effect was observed, which means a larger increase 
in their concentrations are unlikely result in further 
alteration  in  protein  binding  of  M6G  (R2 = 
0.831,  P  = 0.0883, and R2 = 0.557, P = 0.2535, 
respectively). These results are shown in figure 4.
Protein  binding  of  M6G  in  serum  and  plasma 
samples
There  was  no  significant  difference  between  the 
serum and plasma protein binding of M6G (66.7% ± 
1.4 vs. 67.95 % ± 3.0 respectively, P > 0.05).
Effect of storage of blood and buffer samples on 
M6G binding
Storage of serum and spiked buffer at -20°C for 7, 
14, 21 and 28 days before equilibrium dialysis did 
not have any significant effect on serum bound M6G 
when compared with the same day collection and 
dialysis of the samples (P > 0.05). 
DISCUSSION
Only the unbound fraction of drug exerts its clinical 
effects.    Potentially,  the  protein  binding  of  M6G 
could have an impact on its clinical use. Despite 
this, little is known about protein binding of M6G 
in  adulthood,  infancy  or  childhood.  Other  drugs 
such as tubocurarine, metocurine, propranolol, and 
lidocaine  (16)  have  shown  to  have  lower  protein 
Albumin Concentration (g/l)
Effects  of  Human  Serum  albumin,  AAG  and 
nonesterified fatty acids (NEFAs) on M6G binding
A study of the effect of different concentrations of 
HSA in Sorensen’s buffer on M6G binding showed 
that increasing HSA concentration decreased M6G 
free percentage (R2 = 0.827, P = 0.0082, Figure 1) so 
that thee binding ratio of bound to free drug (B/F) of 
M6G in human serum albumin solutions was related 
to albumin concentration up to 70 g/l (R2 = 0.891, 
P = 0.001, Figure 2). The calculated percentage of 
free  M6G  at  43.8  g/l  of  HSA  concentration  (the 
mean albumin concentration in the 18 subjects) was 
68.8 %,  which was very similar to the free percentage 
in  the  healthy  subjects  with  equal  serum  albumin 
concentration (67.7 %).
Addition of AAG (1.0 or 2.0 g/l) did not alter the 
percentages  of  M6G  in  the  free  form  (64.0%  ± 
1.5 and 64.1% ± 1.6 and 67.5% ± 1.6; P < 0.01, 
respectively). Addition of palmitic acid (1.0 mmol/l) to 
HSA (40 g/l) increased the free percentage of M6G 
from 67.5% ± 1.6 to 73.8% ± 2.2 (P < 0.01) and the 
same concentration of oleic acid produced a slightly 
larger increase from 67.5% ± 1.6 to 74.9% ± 0.6 
(P < 0.01).  
Effect  of  pH  and  M6G  concentration  on  M6G 
binding
Free  M6G  was  unaffected  by  pH  in  either  the 
untreated serum (R2 = 0.340, P > 0.05) or the serum, 
which had been adjusted with acid or alkali prior to 
dialysis (R2 = 0.261, P > 0.05). These points when 
combined and subjected to unpaired t test analysis 
revealed  no  significant  difference  between  the 
regression lines (P > 0.05).          
In serum from one volunteer the mean percentage of 
free drug between 1.63 and 118.1 ng/ml was 66.4% 
± 1.7 (n = 9). The relationship between percentage 
of free M6G and total serum M6G concentration 
was  significant  (R2 =  0.600,  P  =  0.014).  Serum 
protein binding of M6G was linearly but negatively 
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Figure 1. The relationship between the percentage of free M6G 
to protein and the concentration of human serum albumin solution 
and in healthy volunteers, neonates and children serum.
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Figure 2. The relationship between the ratio of bound to free 
(B/F) for M6G and the concentration of human serum albumin 
solution in serum of healthy subjects and human serum albumin 
solutions of varied concentrations.
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binding  in  neonatal  blood  than  adult.  Neonates 
may be at particular risk from changes in free drug 
concentration  because  of  immaturity  of  the  heart 
and  the  blood  brain  barrier  (17).  In  this  study  it 
was  attempted  to  simulate  conditions  of  in  vitro 
more closely and to assess some of the factors with 
potential impact on the clinical effects of M6G. These 
factors were selected cancer chemotherapy agents, 
concentrations of the binding proteins; albumin and 
AAG as well as nonesterified fatty acids (NEFA). 
The percentage of free M6G in serum of healthy 
adults was slightly lower than results of a study of 
M6G protein binding in a smaller number of subjects 
(63.3% ± 3.8, n=8) (5) but significantly lower than 
the result of another study which reported 89% ± 
2 free M6G percentages in pooled plasma from 5 
volunteers  (6).  Since  neither  of  studies  provided 
information on their subjects’ protein levels or drug 
concentration, it is difficult to compare directly the 
results  of  the  reported  studies  with  those  of  this 
study.  However,  Vree  and  co-workers  study  was 
performed at room temperature rather than at 37 ºC 
and this tends to result in an increase in the protein 
binding  of  many  drugs  as  previously  reported  in 
cases of morphine (5) and phenytoin (18). While 
lower level of binding reported by Milne and co-
workers  could  be  due  to  binding  to  the  dialysate 
apparatus, there is no information on this matter. The 
difference could be because of the used methods. 
Unlike the present study, in both studies, an Amicon 
micropartition  ultracentrifuge  system  MPS-1  was 
used for measurement of plasma protein binding of 
M6G. In the present study, there was no binding to 
the membrane or the equilibrium dialysis cells and 
also there also was not any leakage of protein or 
buffer solutions to the other compartments or to the 
water bath. 
Previous  study  on  morphine  protein  binding  (9) 
showed that its protein binding in adults, neonates 
and children with cancer was significantly lower than 
M6G free percentages of the present study. M6G is a 
more polar compound than morphine itself and as it 
has been found for other similar compounds, the free 
percentage was higer  (5).
Albumin appears to be the major binding protein 
of M6G and AAG has a much weaker role in M6G 
protein binding. One of the important biological 
activities of AAG is the ability to bind numerous basic 
and neutral lipophilic drugs such as propranolol (19) 
and tricyclic antidepressants (20). In vitro studies 
provided evidence of two classes of binding sites 
for basic and neutral drugs on AAG (21). The extent 
of  binding  of  drugs  to AAG  depends  on  several 
factors such as the conformational changes of AAG, 
polarity  of  ligands,  temperature,  or  pH  (22). The 
lower binding of M6G to AAG could be of any of 
the above factors.
The degree of binding in HSA was very similar to that 
of serum at an equivalent albumin concentration. The 
low correlation between M6G free percentages and 
albumin concentration in the healthy volunteers than 
in the study using HSA alone may be related to the 
narrower range of albumin concentrations observed 
in  the  subjects,  possibly  together  with  effects  of 
other factor(s) such as NEFA concentrations. The 
relationship  between  the  ratio  of  bound  to  free 
(binding ratio) for M6G and the concentration of 
human  serum  albumin  solution  was  significantly 
related to samples of HSA solution, healthy adults, 
neonates and children, implying a constant number 
of binding sites for M6G on HSA molecules and that 
the dissociation constant of the drug protein complex 
is much greater than the free drug concentration (23).
In contrast to expectation, addition of AAG even in 
concentrations higher than that reported in male aged 
20 - 25 years old (0.5 - 1.17 g/l (7)) did not alter the 
binding in the expected direction. This is in marked 
contrast to that of many weakly basic drugs such as 
fentanyl and alfentanil (24), which bind primarily to 
AAG.
Total NEFA in females and male aged 20 - 25 years 
old were reported to be 293 ± 151 and 251 ± 114 µM, 
respectively (7). Palmitic acid and oleic acid each 
make up about one third of the total serum NEFA 
concentration. NEFA have been reported to associate 
with  albumin  (25),  which  generally  contribute  to 
increase  of  the  serum  free  percentages  of  many 
drugs in serum (26). In this study it was shown as 
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a small but significant raise in free percentages of 
M6G in the presence of palmitic acid and oleic acid 
(P < 0.01). NEFA may thus be a determinant of M6G 
binding, although the magnitude of their effects on 
health is likely to be small. 
It was hypothesized that M6G serum free percentages 
could  be  higher  increase  in  drug  concentration 
because of the higher ratio of drug concentration to 
proteins concentration in serum. It was only possible 
to confirm a small but statistically significant raise 
in free M6G by increasing its concentration. It is 
possible  that  higher  concentrations  might  have 
some significant effects, but such concentrations are 
unlikely to be achieved clinically. There was a 
3.4 % change in free percentages of M6G when there 
was an increase in serum concentration from 1.56 to 
118.10 ng/ml. For every one ng/ml increase in serum 
concentration of M6G there was a 0.03% increase 
in M6G free percentages. It seems that changes in 
concentration alter more morphine protein binding 
than  that  of  M6G  (about  5  times  more)  (9). The 
effect of concentration protein binding of morphine 
and M6G together could have additional effects on 
analgesic properties of morphine. 
A  comparison  of  M6G  protein  binding  in  serum 
and  plasma  showed  that  presence  or  absence  of 
fibrinogen in the sample did not alter binding in any 
way, suggesting lack of binding to fibrinogen. In 
vitro addition of heparin to plasma did not affect the 
protein binding of M6G, which was similar to that 
reported by Spector (26) for some other drugs. 
Morphine and 6-MP concentrations did not cause 
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